Eva I. Hyde

Dr. Eva I. Hyde


Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PRPaul R. Race
Paul R. Race
ALAndrew L. Lovering
Andrew L. Lovering
RGRichard M. Green
Richard M. Green
AOAbdelmijd Ossor
Abdelmijd Ossor
SWScott A. White
Scott A. White
EHEva I. Hyde
Eva I. Hyde
The antibiotics nitrofurazone and nitrofurantoin are used in the treatment of genitourinary infections and as topical antibacterial agents. Their action is dependent upon activation by bacterial nitroreductase flavoproteins, including the Escherichia coli nitroreductase (NTR). Here we show that the products of reduction of these antibiotics by NTR are the hydroxylamine derivatives. We show that the reduction of nitrosoaromatics is enzyme-catalyzed, with a specificity constant ∼10,000-fold greater than that of the starting nitro compounds. This suggests that the reduction of nitro groups proceeds through two successive, enzyme-mediated reactions and explains why the nitroso intermediates are not observed. The global reaction rate for nitrofurazone determined in this study is over 10-fold higher than that previously reported, suggesting that the enzyme is much more active toward nitroaromatics than previously estimated. Surprisingly, in the crystal structure of the oxidized NTR-nitrofurazone complex, nitrofurazone is oriented with its amide group, rather than the nitro group to be reduced, positioned over the reactive N5 of the FMN cofactor. Free acetate, which acts as a competitive inhibitor with respect to NADH, binds in a similar orientation. We infer that the orientation of bound nitrofurazone depends upon the redox state of the enzyme. We propose that the charge distribution on the FMN rings, which alters upon reduction, is an important determinant of substrate binding and reactivity in flavoproteins with broad substrate specificity.

25 November 2004 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
PSPeter F Searle
Peter F Searle
MCMing‐Jen Chen
Ming‐Jen Chen
LHLongqin Hu
Longqin Hu
PRPaul R Race
Paul R Race
ALAndrew L Lovering
Andrew L Lovering
EHEva I. Hyde
Eva I. Hyde

1 May 2001 in Journal of Molecular Biology
Verified
Journal Article
Closed access
ALAndrew L Lovering
Andrew L Lovering
EHEva I. Hyde
Eva I. Hyde
PSPeter F Searle
Peter F Searle
SWScott A White
Scott A White

17 December 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JWJoseph Wade
Joseph Wade
TBTamara A. Belyaeva
Tamara A. Belyaeva
EHEva I. Hyde
Eva I. Hyde
SBSteve John Williams Busby
Steve John Williams Busby
The Escherichia coli melAB promoter is co‐dependent upon two transcription activators, MelR and the cyclic AMP receptor protein, CRP. In this study we demonstrate positive co‐operativity between the binding of MelR and CRP at the melAB promoter, which provides a simple mechanism for its co‐dependence. MelR binds to four sites, centred at positions −42.5, −62.5, −100.5 and −120.5 relative to the melAB transcription start point. When MelR is pre‐bound, CRP is able to bind to a target located between MelR at positions −62.5 and −100.5. This increases the occupation of the two downstream sites for MelR, which is essential for transcription activation. We have identified residues within activating region 1 (AR1) of CRP that are important in transcription activation of the melAB promoter. At simple CRP‐dependent promoters, the surface of CRP containing these residues is involved in contacting the RNA polymerase α subunit. Our results show that, at the melAB promoter, the surface of CRP containing AR1 contacts MelR rather than RNA polymerase. Thus, MelR and CRP activate transcription by a novel mechanism in which they bind co‐operatively to adjacent sites and form a bacterial enhanceosome.

19 May 2009 in British Journal of Cancer
Verified
Journal Article
Open access
SVS O Vass
S O Vass
DJD Jarrom
D Jarrom
WWW R Wilson
W R Wilson
EHEva I. Hyde
Eva I. Hyde
PSP F Searle
P F Searle
Prodrug activation gene therapy is a developing approach to cancer treatment, whereby prodrug-activating enzymes are expressed in tumour cells. After administration of a non-toxic prodrug, its conversion to cytotoxic metabolites directly kills tumour cells expressing the activating enzyme, whereas the local spread of activated metabolites can kill nearby cells lacking the enzyme (bystander cell killing). One promising combination that has entered clinical trials uses the nitroreductase NfsB from Escherichia coli to activate the prodrug, CB1954, to a potent bifunctional alkylating agent. NfsA, the major E. coli nitroreductase, has greater activity with nitrofuran antibiotics, but it has not been compared in the past with NfsB for the activation of CB1954. We show superior in vitro kinetics of CB1954 activation by NfsA using the NADPH cofactor, and show that the expression of NfsA in bacterial or human cells results in a 3.5- to 8-fold greater sensitivity to CB1954, relative to NfsB. Although NfsB reduces either the 2-NO2 or 4-NO2 positions of CB1954 in an equimolar ratio, we show that NfsA preferentially reduces the 2-NO2 group, which leads to a greater bystander effect with cells expressing NfsA than with NfsB. NfsA is also more effective than NfsB for cell sensitisation to nitrofurans and to a selection of alternative, dinitrobenzamide mustard (DNBM) prodrugs.

10 October 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LHLongqin Hu
Longqin Hu
CYChengzhi Yu
Chengzhi Yu
YJYongying Jiang
Yongying Jiang
JHJiye Han
Jiye Han
ZLZhuorong Li
Zhuorong Li
EHEva I. Hyde
Eva I. Hyde